- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 20 ...

- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 20 ...

 - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase ...

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA. The poster, ...

Core Insights - Alterity Therapeutics presented significant findings at the American Academy of Neurology (AAN) 2024 Annual Meeting regarding ATH434, a potential treatment for Parkinson's disease and Multiple System Atrophy (MSA) [1][2] Group 1: ATH434 Clinical Trials - ATH434-201 Phase 2 clinical trial involves 65 participants diagnosed with early-stage MSA, focusing on fluid biomarkers and neuroimaging data [3] - The trial aims to demonstrate the efficacy of ATH434 in redistributing excess labile iron, inhibiting α-synuclein aggregation, and reducing oxidative stress [3][8] - The study enrolled 77 adults, with treatment lasting 12 months to assess changes in efficacy endpoints [8] Group 2: Biomarker Insights - Baseline data from the ATH434-201 trial indicated elevated plasma Neurofilament Light Chain (NfL) levels correlated with disease severity in MSA patients [2][3] - The bioMUSE Natural History Study highlighted the aggressive progression of MSA and the potential of NfL as a biomarker for tracking disease progression [5][10] Group 3: Preclinical Findings - In a primate model, ATH434 treatment resulted in improved motor performance and reduced iron levels in the substantia nigra, supporting its potential for treating Parkinson's disease [6] - The study showed that all six ATH434-treated macaques had stable or improving scores, while two of three vehicle-treated macaques did not demonstrate improvement [6] Group 4: Company Overview - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, with ATH434 being its lead candidate [7][13] - The company has received Orphan drug designation for ATH434 for the treatment of MSA from the U.S. FDA and the European Commission [7]

Core Viewpoint - Alterity Therapeutics is advancing its lead candidate ATH434, an oral agent targeting neurodegenerative diseases, with new data to be presented at upcoming medical conferences, highlighting its potential in treating conditions like Multiple System Atrophy (MSA) and Parkinson's disease [1][2][3]. Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, particularly through its lead asset ATH434 [9]. - The company is based in Melbourne, Australia, and San Francisco, California, and is dedicated to creating innovative therapies for patients suffering from these conditions [9]. Product Information - ATH434 is designed to inhibit the aggregation of pathological proteins associated with neurodegeneration, showing preclinical efficacy in reducing α-synuclein pathology and restoring normal iron balance in the brain [3]. - The drug has completed Phase 1 studies, demonstrating good tolerance and achieving brain levels comparable to effective doses in animal models of MSA [3]. Clinical Trials - ATH434 is currently being evaluated in two Phase 2 clinical trials: ATH434-201, a randomized, double-blind, placebo-controlled trial for early-stage MSA, and ATH434-202, an open-label biomarker trial for more advanced MSA [3][4]. - The ATH434-201 trial involves 77 adults receiving either ATH434 or placebo over 12 months, focusing on neuroimaging and protein biomarkers to assess efficacy and safety [5]. Research and Development - The bioMUSE study, in collaboration with Vanderbilt University Medical Center, tracks MSA progression and informs the design of the ATH434-201 trial, providing critical data on early-stage MSA patients [6]. - The study has enrolled approximately 20 individuals with clinically probable or established MSA, contributing to the understanding of disease progression and biomarker selection [6]. Disease Context - Multiple System Atrophy (MSA) is a rare neurodegenerative disease affecting at least 15,000 individuals in the U.S., characterized by autonomic dysfunction and impaired movement, with no approved therapies to slow its progression [7]. - Parkinson's disease, another focus area for ATH434, affects nearly one million people in the U.S. and is marked by motor and non-motor symptoms due to the loss of dopamine-producing brain cells [8].

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23- 25, 2024 in Boston, MA. Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Title: Friedreich’s A ...

Exhibit 99.1 HALF-YEAR REPORT 2023 An Alternate Future Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) ACN 080 699 065 Lodged with the ASX under Listing Rule 4.3A. This information should be read in conjunction with the Annual report. of Alterity Alterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2023 | --- | --- | |----------------------------|--------------------------------------------------------| | | | | Name of entity: ABN: | Alterity Therapeutics Limited 37 080 ...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters f ...

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its second review of trial data and recommended the ATH434-201 Phas ...